- Advertising
- Asia
- Bangladesh
- Biological Inventions
- BRAND VALUATION
- China
- Comparative Advertisement
- Copyright
- Copyright Infringement
- Copyright Litigation
- Counterfeiting
- Covid
- Data Protection
- Design
- Digital Marketing Rights
- DRM
- Electronics
- Geographical Indication
- India
- Indian Patents Act
- Indonesia
- Intellectual Property
- Interim Injunction
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB
- IPAB Decisions
- Japan
- Legal Issues
- Licensing
- Malaysia
- Myanmar
- NCLT
- NEPAL
- Net Neutrality
- News & Updates
- Office
- Patent Commercialisation
- Patent Cooperation Treaty
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Opposition
- Patent Prosecution
- Patent Rule Amendment
- Patent Term Extension
- Patents
- pharma
- Philippines
- Punitive Damages
- Section 3(D)
- section 64
- Singapore
- South-east Asia
- Technology
- Technology Transfer
- Thailand
- Trademark
- Trademark Litigation
- UAE
- Uncategorized
- USPTO
- Vietnam
- WIPO
Patenting of a Drug Under IPR.
December 9, 2022 - 11:19 am
Categories:
drug
pharma
Pharma- biotech- Patent Commercialisation
2 Comments INTRODUCTION This particular blog is on the subject matter that how a drug patent can be obtained under the patent law in India and in this context the landmark judgement of the Supreme court- Novartis v. Union of India has been covered in this blog. In this blog the various facets with respect to getting … Continue reading Patenting of a Drug Under IPR.
Read more »The Nagoya Protocol – Convention on Biological Diversity
July 21, 2014 - 9:10 am
Categories:
News & Updates
Patent Commercialisation
Patents
Pharma- biotech- Patent Commercialisation
0 Comments A new international treaty named the “Nagoya Protocol” will be giving some relief to India and other developing countries. The Nagoya Protocol on Access to Genetic Resources with the objective of ensuring access of genetic resources to the signatory countries and ensuring fair and equitable sharing of benefit to the local community and signatory country … Continue reading The Nagoya Protocol – Convention on Biological Diversity
Read more »Two-Days International Symposium on Strategies for Managing Pharmaceutical, Biotechnology & Chemical Patent Portfolios
December 13, 2013 - 7:42 am
Categories:
Advertising
News & Updates
Pharma- biotech- Patent Commercialisation
0 Comments We are happy to inform you all that IIPRD and Khurana & Khurana, in association with Cantor Colburn (US) and Fukami Patent Office (Japan) are holding an International Patent Symposium covering all major and relevant Pharmaceutical/Biotechnology Related Patent issues in the month of February 2014 in India. The Two-Days International Symposium would be covering Strategies … Continue reading Two-Days International Symposium on Strategies for Managing Pharmaceutical, Biotechnology & Chemical Patent Portfolios
Read more »Natco Files India’s First Compulsory Licensing Application
September 14, 2011 - 4:38 am
Categories:
Patent Commercialisation
Pharma- biotech- Patent Commercialisation
0 Comments Natco Pharma has filed India’s first Compulsory Licensing (CL) Application (in accordance with Section 84(1) of the Indian Patents Act) against one of the Bayer’s patented drug Sorafenib, marketed by Bayer as Nexavar for treating Kidney and Liver Cancer. Patent on Sorafenib is granted in India on 03.03.2008 having number IN 215758. This will be … Continue reading Natco Files India’s First Compulsory Licensing Application
Read more »Inventors – All Technologies Are not Worth Billions
July 31, 2011 - 6:23 pm
Categories:
high-tech-patent-commercialisation
Patent Commercialisation
Pharma- biotech- Patent Commercialisation
0 Comments Working in the IP/Technology Commercialization and Out-Licensing domain makes you assess and evaluate the commercial viability of numerous IP backed inventions across technology domains. Apart from learning about and assessing new technologies, we also tend to learn quite a lot about Inventors’ mindset, specifically about their perspective of their own inventions. This article relates to … Continue reading Inventors – All Technologies Are not Worth Billions
Read more »Anti Cancer drug: Making it Patient-driven, not Disease-driven
April 11, 2011 - 10:16 am
Categories:
Patent Commercialisation
Pharma- biotech- Patent Commercialisation
0 Comments Introduction: French compatriots Ipsen and bioMérieux, have been few most potential companies since 2007 in the development of companion assay to assess patient benefit from a compound useful for treating several severe forms of cancers. The partnership between two companies has focused on the two main broad areas of pharma research: Personalized medicine and Theranostics. … Continue reading Anti Cancer drug: Making it Patient-driven, not Disease-driven
Read more »Food Market making Profit from Climatic Changes
March 14, 2011 - 7:15 am
Categories:
Patent Commercialisation
Pharma- biotech- Patent Commercialisation
0 Comments Climatic changes being a source of making a profit for food crop manufacturers. Adverse changes in climate have triggered the ecosystems affecting crops, livestock, fisheries and forests, and the billions of people whose livelihoods depend on them. Extreme climate events (especially hotter, drier conditions in semi-arid regions) are likely to slash yields for maize, wheat, … Continue reading Food Market making Profit from Climatic Changes
Read more »Indian Pharmaceutical Industry Licensing Deals: Case Studies
June 14, 2010 - 10:36 am
Categories:
Patent Commercialisation
Pharma- biotech- Patent Commercialisation
1 Comments Glenmark Pharmaceuticals Glenmark, research-driven, global, integrated pharmaceutical company with Research Focus on Inflammatory Diseases, Metabolic Disorders and Pain has a presence in over 80 countries around the world. The Company has a proven track record of entering into Licensing deals with Big Pharma and entered into Outlicensing deals in 2004 with Forest laboratories for Oglemilast, … Continue reading Indian Pharmaceutical Industry Licensing Deals: Case Studies
Read more »